文献速递肺外科

化疗联合免疫检查点抑制剂用于可手术IIIA/B(N2)非小细胞肺癌的手术结局

CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes.
PubMed 文献 · Ann Thorac Surg · 2026-08-05

这项单臂II期试验在美国9家医院入组37例病理证实N2+的可切除III期NSCLC患者,接受4周期铂类双药+度伐利尤单抗后行肺叶或更大范围切除,并辅助度伐利尤单抗1年。30例(81%)接受手术,R0切除28/30(93.3%),全肺切除率6.7%,微创手术19/30(63.3%),30天和90天无死亡。

要点

  • N2+ NSCLC新辅助化疗联合度伐利尤单抗后,81%患者可接受手术。
  • R0切除率93.3%,微创手术率63.3%,全肺切除率仅6.7%。
  • 30天和90天无死亡,术后中位住院3.5天。

核心结论

  • N2+ NSCLC患者接受新辅助化疗联合度伐利尤单抗后手术可行,无死亡且R0切除率和微创手术率高。
  • 该场景下手术可获得良好结局,值得在多学科NSCLC诊疗中更充分考虑。

研究设计与样本

  • 单臂II期试验,在美国9家医院入组,2021至2023年共37例可切除III期病理证实N2+的NSCLC患者。
  • 患者接受4周期铂类双药+度伐利尤单抗,随后行肺叶或更大范围切除,并辅助度伐利尤单抗1年。

主要发现

  • 37例入组患者中30例(81%)接受切除。
  • R0切除28/30(93.3%),全肺切除2/30(6.7%),30天和90天无死亡。
  • 微创手术19/30(63.3%,其中VATS 2例、机器人17例),中转开胸2例,总开胸率11/30(36.7%)。
  • 14/30(46.7%)报告手术难度增加。
  • 新辅助治疗至手术中位间隔46天,手术至辅助治疗中位间隔35天,推荐辅助治疗的23例全部接受。

临床怎么用

  • 对可切除III期N2+ NSCLC,新辅助化疗联合度伐利尤单抗后应积极评估手术切除。
  • 术后应尽早恢复肿瘤辅助治疗,本研究中手术至辅助治疗中位间隔35天。

局限性

  • 单臂II期试验,样本量37例,无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is renewed interest in resection of Stage III (N2+) NSCLC given impressive outcomes with neoadjuvant/perioperative chemoimmunotherapy (ChIO). We report surgical outcomes from an exclusively N2+ NSCLC clinical trial following chemotherapy + durvalumab. METHODS: This was a single arm phase II trial enrolled at 9 US hospitals. Eligible patients had resectable stage III NSCLC, pathologically proven N2+. Patients received 4 cycles of platinum doublet + durvalumab followed by lobectomy or greater, and adjuvant durvalumab for 1 year. Surgical approach, margins, extent of lymphadenectomy, complications, and treatment timeliness were analyzed. RESULTS: From 2021-2023, 37 patients were enrolled; 30 patients underwent resection (81%). Surgical outcomes are notable for R0 resection in 28/30 patients (93.3%), pneumonectomy rate of 6.7% (2/30), median stay 3.5 days, no mortality at 30 and 90 days. Minimally invasive surgery was possible in 19/30 (63.3%: 2 VATS, 17 robotic), with 2 conversions to thoracotomy (total thoracotomy rate: 11/30: 36.7%). Increased surgical difficulty was reported in 14/30 (46.7%). Median interval from neoadjuvant therapy to surgery was 46 days, and from surgery to adjuvant therapy was 35 days. All 23 patients recommended for adjuvant therapy received it. CONCLUSIONS: This trial provides insight into surgical outcomes for prospectively documented N2+ NSCLC treated with neoadjuvant ChIO. Surgery in this challenging scenario was accomplished with no mortality, high rates of minimally invasive surgery, R0 resection, and lobectomy, with prompt return to oncologic therapy. Following ChIO, resection of N2+ NSCLC can be achieved with excellent outcomes and warrants stronger consideration within multidisciplinary NSCLC care.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Martin LW, Wang X, Kozono D, et al. CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes. Ann Thorac Surg. 2026. PMID: 42556446. doi:10.1016/j.athoracsur.2026.07.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。